Diabetes mellitus type 2 drives metabolic reprogramming to promote pancreatic cancer growth.

Guermarie Velazquez-TorresEnrique Fuentes-MatteiHyun Ho ChoiSai-Ching J YeungXiangqi MengMong-Hong Lee
Published in: Gastroenterology report (2020)
Diabetes mellitus type 2 has critical effects that promote pancreatic cancer progression via transcriptomic and metabolomic changes. Our animal models provide strong evidence for the causal relationship between diabetes and accelerated pancreatic cancers. This study sheds a new insight into the effects of metformin and its potential as part of therapeutic interventions for pancreatic cancer in diabetic patients.